Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Source:http://linkedlifedata.com/resource/pubmed/id/10090116

Arch. Intern. Med. 1999 Mar 22 159 6 593-600

Download in:

View as

Triples

General Info

PMID
10090116